Stockreport

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference [Yahoo! Finance]

Nanobiotix S.A. - ADSs  (NBTX) 
PDF re-irradiation with JNJ-1900 (NBTXR3) for patients with unresectable, locoregional recurrent NSCLC to be presented by principal investigator Dr. Saumil Gandhi at 8:00 AM [Read more]